MAPT and Alzheimer disease: Clinical and neuropathological studies have greatly advanced our knowledge and revealed that accumulation of amyloid-beta peptide (Aβ) in the brain, which starts decades before symptoms appear, triggers AD pathogenesis, driving neurofibrillary tau pathology, and progressive synaptic, neuronal, and axonal damage [1,2,3].